PegaptanibIn Exudative Age-Related Macular Degeneration

被引：0
作者：
M. Asif A. Siddiqui
Gillian M. Keating
机构：
[1] Adis International Limited,
来源：
Drugs | 2005年 / 65卷
关键词：
Vascular Endothelial Growth Factor; Visual Acuity; Verteporfin; Pegaptanib; Sham Injection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Pegaptanib, an aptamer, is an antagonist of vascular endothelial growth factor that has shown efficacy in the treatment of patients with exudative age-related macular degeneration (AMD).
引用
收藏
页码：1571 / 1577
页数：6
相关论文
共 33 条
  • [1] Hooper CY(2003)New treatments in age-related macular degeneration Clin Experiment Ophthalmol 31 376-91
  • [2] Guymer RH(2004)Innovative treatments for exudative age-related macular degeneration Int Ophthalmol Clin 44 41-50
  • [3] Kim RW(2003)Potential public health impact of Age-Related Eye Disease Study results: AREDS report no 11. Arch Ophthalmol 121 1621-4
  • [4] Heier JS(2004)Age-related macular degeneration is the leading cause of blindness… JAMA 291 1900-1
  • [5] Bressler NM(2004)Current and future treatment options for nonexudative and exudative age-related macular degeneration Drugs Aging 21 967-92
  • [6] Bressler SB(2004)The epidemiology of age-related macular degeneration Int Ophthalmol Clin 44 17-39
  • [7] Congdon NG(2004)Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 564-72
  • [8] Bressler NM(1991)Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials Arch Ophthalmol 109 1109-14
  • [9] Comer GM(1999)Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials — TAP report Arch Ophthalmol 117 1329-45
  • [10] Ciulla TA(1999)Oligonucleotide NX1838 inhibits VEGF In Vitro Cell Dev Biol Anim 35 533-42
1234